Stock IMVT IMMUNOVANT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Immunovant, Inc.

Equities

IMVT

US45258J1025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
28.78 USD +0.91% Intraday chart for Immunovant, Inc. -0.07% -31.69%
Apr. 20 Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing MT
Apr. 20 Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing
Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing
Immunovant Posts Narrower Fiscal Q3 Loss
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Immunovant Insider Sold Shares Worth $383,012, According to a Recent SEC Filing
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates
Top Premarket Decliners
Immunovant Insider Sold Shares Worth $490,697, According to a Recent SEC Filing
Immunovant Insider Sold Shares Worth $504,567, According to a Recent SEC Filing
Immunovant Insider Sold Shares Worth $490,668, According to a Recent SEC Filing
Sector Update: Health Care Stocks Decline Premarket Tuesday
Roivant Sciences' Immunovant Reports 'Positive' Initial Data From Phase 1 Study of IMVT-1402
Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults
Immunovant, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Immunovant Insider Sold Shares Worth $142,349, According to a Recent SEC Filing
Immunovant Insider Sold Shares Worth $168,244, According to a Recent SEC Filing
Sector Update: Health Care Stocks Advancing Late Afternoon
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMVT Stock
  4. News Immunovant, Inc.
  5. Other languages